Marshall P. Goren

Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatinum(II) therapy.

Marshall P. Goren, Reba K. Wright, Charles B. Pratt et al. · PubMed · 1987 · 112 citations

Urology, Oncology, Ifosfamide Neurotoxicity +15

Cumulative renal tubular damage associated with cisplatin nephrotoxicity

Marshall P. Goren, Reba K. Wright, Marc E. Horowitz · Cancer Chemotherapy and Pharmacology · 1986 · 94 citations

Urology, Renal Disease, Pathology +6

Pharmacokinetic and toxicity evaluation of five-day continuous infusion versus intermittent bolus cis-diamminedichloroplatinum(II) in head and neck cancer patients.

A A Forastiere, J. Belliveau, Marshall P. Goren et al. · PubMed · 1988 · 88 citations

Neck Cancer, Pharmacotherapy, Toxicity Evaluation +16

Ifosfamide neurotoxicity is related to previous cisplatin treatment for pediatric solid tumors.

C B Pratt, Marshall P. Goren, William H. Meyer et al. · Journal of Clinical Oncology · 1990 · 68 citations

Pediatric Solid Tumors, Relative Risk, Pharmacotherapy +16

A phase I-II trial of carboplatin and 5-fluorouracil combination chemotherapy in advanced carcinoma of the head and neck.

Arlene A. Forastiere, Ronald B. Natale, Bonnie J. Takasugi et al. · Journal of Clinical Oncology · 1987 · 55 citations

Incurable Head, Neck Cancer, Pathology +16